2025 BioPharma Deals: The Survival Series | Nov 24-25 | Munich, Germany

BioPharma Deals: The Survival Series brings together leaders from biotech, pharma, investment, CRO/CDMO, legal, and advisory sectors for a high-impact event focused on pragmatic deal-making, new financing models, early IPOs, and unconventional partnerships.This is not a conference about the distant future. It's a working summit for what can be done now. It's about survival,…

BySaurabh ChaubeyAugust 18, 2025

SPOTLIGHT

CXO Talks: Colin Banas from DrFirst in an Illuminating Conversation with PharmaShots

In the CXO Talks podcast, PharmaShots engaged in a riveting dialogue exchange with Colin Banas, Chief Medical Officer at DrFirst. Colin highlights the evolution of DrFirst from becoming a leader in the e-prescribing space to an end-to-end medication management company Colin talks about its collaborators, Wise Hospice Options, achieving a new milestone by reducing the…

ByHimanshu SehgalMay 12, 2025

NEWS

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…

ByPrince GiriJanuary 15, 2025

INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:  In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal valueThis report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…

ByPrince GiriJanuary 15, 2025

INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02)

Shots: In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B Propelled by the invaluable…

BySenior EditorJanuary 15, 2024

INSIGHTS+

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)

Shots:As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01)The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchasesPropelled by the invaluable…

BySenior EditorJanuary 4, 2024

2025 BioPharma Deals: The Survival Series | Nov 24-25 | Munich, Germany

CXO Talks: Colin Banas from DrFirst in an Illuminating Conversation with PharmaShots

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02)

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)

Contact US

OUR INFORMATION

FOLLOW US